Who is sponsoring SCENIC?

SCENIC is sponsored by Respivant Sciences GmbH.

What condition does SCENIC study?

SCENIC studies Persistent Cough in IPF, Chronic Cough, IPF.

What drugs are being tested in SCENIC?

Interventions: RVT-1601, Placebo.

What is the status of SCENIC?

SCENIC is currently TERMINATED.

Last reviewed 2020-06-11 · How we verify

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF (SCENIC)

NCT03864328 PHASE2 TERMINATED

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough. Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy. Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.

Details

Lead sponsor	Respivant Sciences GmbH
Phase	PHASE2
Status	TERMINATED
Enrolment	108
Start date	Fri Mar 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Persistent Cough in IPF
Chronic Cough
IPF

Interventions

RVT-1601
Placebo

Countries

Italy, New Zealand, Netherlands, Belgium, United Kingdom, Germany, Canada, Australia, United States, Turkey (Türkiye), Czechia